OrbiMed Genesis GP LLC bought $10.0M of Edgewise Therapeutics (EWTX)
Executed Apr 3 2025, disclosed Apr 4 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Apr 4 2025), the stock returned +30.5% (delay-adjusted); from the execution session (Apr 3 2025), +13.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
OrbiMed Genesis GP LLC (Director) filed 2 Form 4 reports as a reporting entity in the past 24 months (2 purchases, 0 sales), most often in Edgewise Therapeutics, Inc. (EWTX). Across 2 priced purchase filings, the average 21-session return was +5.7% from execution and +4.1% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of EWTX (496,771 sh across 2 lots, as filed), executed Apr 3 2025.
Healthcare · Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle dis…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→